There is 1 version of this bill. View text

Click the check-box to add or remove the section, click the text link to scroll to that section.
Titles Actions Overview All Actions Cosponsors Committees Related Bills Subjects Latest Summary All Summaries

Titles (2)

Short Titles

Short Titles - House of Representatives

Short Title(s) as Introduced

Elijah E. Cummings Lower Drug Costs Now Act

Official Titles

Official Titles - House of Representatives

Official Title as Introduced

To establish a fair price negotiation program, protect the Medicare program from excessive price increases, and establish an out-of-pocket maximum for Medicare part D enrollees, and for other purposes.


Actions Overview (1)

Date Actions Overview
04/22/2021Introduced in House

All Actions (8)

Date All Actions
04/27/2021Referred to the Subcommittee on Oversight and Investigations.
Action By: Committee on Veterans' Affairs
04/23/2021Referred to the Subcommittee on Health.
Action By: Committee on Energy and Commerce
04/22/2021Referred to the Committee on Energy and Commerce, and in addition to the Committees on Ways and Means, Education and Labor, Oversight and Reform, and Veterans' Affairs, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Action By: House of Representatives
04/22/2021Referred to the Committee on Energy and Commerce, and in addition to the Committees on Ways and Means, Education and Labor, Oversight and Reform, and Veterans' Affairs, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Action By: House of Representatives
04/22/2021Referred to the Committee on Energy and Commerce, and in addition to the Committees on Ways and Means, Education and Labor, Oversight and Reform, and Veterans' Affairs, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Action By: House of Representatives
04/22/2021Referred to the Committee on Energy and Commerce, and in addition to the Committees on Ways and Means, Education and Labor, Oversight and Reform, and Veterans' Affairs, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Action By: House of Representatives
04/22/2021Referred to the Committee on Energy and Commerce, and in addition to the Committees on Ways and Means, Education and Labor, Oversight and Reform, and Veterans' Affairs, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Action By: House of Representatives
04/22/2021Introduced in House
Action By: House of Representatives

Cosponsors (71)

* = Original cosponsor
CosponsorDate Cosponsored
Rep. Neal, Richard E. [D-MA-1]* 04/22/2021
Rep. Scott, Robert C. "Bobby" [D-VA-3]* 04/22/2021
Rep. Welch, Peter [D-VT-At Large] 04/26/2021
Rep. Suozzi, Thomas R. [D-NY-3] 04/26/2021
Rep. Kildee, Daniel T. [D-MI-5] 04/26/2021
Rep. Barragan, Nanette Diaz [D-CA-44] 04/26/2021
Rep. Evans, Dwight [D-PA-3] 04/26/2021
Rep. Davis, Danny K. [D-IL-7] 04/26/2021
Rep. Wilson, Frederica S. [D-FL-24] 04/26/2021
Rep. Thompson, Mike [D-CA-5] 04/26/2021
Rep. Gomez, Jimmy [D-CA-34] 04/26/2021
Rep. DeGette, Diana [D-CO-1] 04/26/2021
Rep. Dingell, Debbie [D-MI-12] 04/26/2021
Rep. Horsford, Steven [D-NV-4] 04/26/2021
Rep. Larson, John B. [D-CT-1] 04/26/2021
Rep. Doyle, Michael F. [D-PA-18] 04/26/2021
Rep. Mfume, Kweisi [D-MD-7] 04/26/2021
Rep. McNerney, Jerry [D-CA-9] 04/26/2021
Rep. Soto, Darren [D-FL-9] 04/26/2021
Del. Sablan, Gregorio Kilili Camacho [D-MP-At Large] 04/26/2021
Rep. Kaptur, Marcy [D-OH-9] 04/26/2021
Rep. Blumenauer, Earl [D-OR-3] 04/26/2021
Rep. Hayes, Jahana [D-CT-5] 04/26/2021
Rep. Sarbanes, John P. [D-MD-3] 04/26/2021
Rep. Castro, Joaquin [D-TX-20] 04/26/2021
Rep. Rush, Bobby L. [D-IL-1] 04/26/2021
Rep. Morelle, Joseph D. [D-NY-25] 04/26/2021
Rep. Case, Ed [D-HI-1] 04/26/2021
Rep. Moore, Gwen [D-WI-4] 05/04/2021
Del. Norton, Eleanor Holmes [D-DC-At Large] 05/04/2021
Rep. Courtney, Joe [D-CT-2] 05/04/2021
Rep. Beatty, Joyce [D-OH-3] 05/04/2021
Rep. Fletcher, Lizzie [D-TX-7] 05/04/2021
Rep. Castor, Kathy [D-FL-14] 05/04/2021
Rep. DeSaulnier, Mark [D-CA-11] 05/14/2021
Rep. Wild, Susan [D-PA-7] 05/14/2021
Rep. Larsen, Rick [D-WA-2] 05/14/2021
Rep. Slotkin, Elissa [D-MI-8] 05/14/2021
Rep. Craig, Angie [D-MN-2] 05/14/2021
Rep. Casten, Sean [D-IL-6] 05/14/2021
Rep. Cooper, Jim [D-TN-5] 05/14/2021
Rep. Ruppersberger, C. A. Dutch [D-MD-2] 05/20/2021
Rep. Underwood, Lauren [D-IL-14] 05/20/2021
Rep. Lieu, Ted [D-CA-33] 05/20/2021
Rep. Connolly, Gerald E. [D-VA-11] 05/20/2021
Rep. Cartwright, Matt [D-PA-8] 05/20/2021
Rep. Carbajal, Salud O. [D-CA-24] 05/20/2021
Rep. Torres, Ritchie [D-NY-15] 05/20/2021
Rep. Blunt Rochester, Lisa [D-DE-At Large] 05/28/2021
Rep. Allred, Colin Z. [D-TX-32] 05/28/2021
Rep. Maloney, Sean Patrick [D-NY-18] 05/28/2021
Rep. Ryan, Tim [D-OH-13] 05/28/2021
Rep. Pappas, Chris [D-NH-1] 05/28/2021
Rep. Frankel, Lois [D-FL-21] 05/28/2021
Rep. McCollum, Betty [D-MN-4] 06/08/2021
Rep. Crist, Charlie [D-FL-13] 06/08/2021
Rep. Garcia, Sylvia R. [D-TX-29] 06/08/2021
Rep. Bustos, Cheri [D-IL-17] 06/25/2021
Rep. Spanberger, Abigail Davis [D-VA-7] 06/25/2021
Rep. Auchincloss, Jake [D-MA-4] 06/25/2021
Rep. Cleaver, Emanuel [D-MO-5] 06/29/2021
Rep. Williams, Nikema [D-GA-5] 06/29/2021
Rep. Deutch, Theodore E. [D-FL-22] 07/06/2021
Rep. Waters, Maxine [D-CA-43] 07/06/2021
Rep. Jacobs, Sara [D-CA-53] 07/06/2021
Rep. Brown, Anthony G. [D-MD-4] 07/20/2021
Rep. Maloney, Carolyn B. [D-NY-12] 07/20/2021
Rep. Stansbury, Melanie Ann [D-NM-1] 07/20/2021
Rep. Langevin, James R. [D-RI-2] 07/20/2021
Rep. Strickland, Marilyn [D-WA-10] 07/20/2021
Rep. Norcross, Donald [D-NJ-1] 07/20/2021

Committees (5)

Committees, subcommittees and links to reports associated with this bill are listed here, as well as the nature and date of committee activity and Congressional report number.

Committee / Subcommittee Date Activity Related Documents
House Energy and Commerce04/22/2021 Referred to
House Energy and Commerce Subcommittee on Health04/23/2021 Referred to
House Ways and Means04/22/2021 Referred to
House Education and Labor04/22/2021 Referred to
House Oversight and Reform04/22/2021 Referred to
House Veterans' Affairs04/22/2021 Referred to
House Veterans' Affairs Subcommittee on Oversight and Investigations04/27/2021 Referred to

A related bill may be a companion measure, an identical bill, a procedurally-related measure, or one with text similarities. Bill relationships are identified by the House, the Senate, or CRS, and refer only to same-congress measures.


Latest Summary (1)

There is one summary for H.R.3. View summaries

Shown Here:
Introduced in House (04/22/2021)

Elijah E. Cummings Lower Drug Costs Now Act

This bill establishes several programs and requirements relating to the prices of prescription drugs.

In particular, the bill requires the Department of Health and Human Services (HHS) to negotiate prices for certain drugs (current law prohibits HHS from doing so). Specifically, HHS must negotiate maximum prices for single-source, brand-name drugs that lack certain generics and that are among either the 125 drugs that account for the greatest national spending or the 125 drugs that account for the greatest Medicare spending. HHS must negotiate the prices of at least 25 such drugs for 2024 and of at least 50 such drugs thereafter and must also negotiate prices for certain newly approved drugs and for insulin products. The negotiated prices must be offered under Medicare and may also be offered under private health insurance unless the insurer opts out.

The negotiated maximum price may not exceed (1) 120% of the average price in Australia, Canada, France, Germany, Japan, and the United Kingdom; or (2) if such information is not available, 85% of the U.S. average manufacturer price. Drug manufacturers that fail to comply with the bill's negotiation requirements are subject to civil and tax penalties.

The bill also makes a series of additional changes to Medicare prescription drug coverage and pricing, including by (1) requiring drug manufacturers to issue rebates to the Centers for Medicare & Medicaid Services for covered drugs that cost $100 or more and for which the average manufacturer price increases faster than inflation; and (2) reducing the annual out-of-pocket spending threshold, and eliminating beneficiary cost-sharing above this threshold, under the Medicare prescription drug benefit.

The bill also requires drug manufacturers to report specified information for certain high-cost drugs, and it provides funds for opioid epidemic initiatives and biomedical research.